Stuhlmann-Laeisz Christiane, Borchert Alisa, Quintanilla-Martinez Leticia, Hoeller Sylvia, Tzankov Alexandar, Oschlies Ilske, Kreuz Markus, Trappe Ralf, Klapper Wolfram
a Department of Pathology , Hematopathology Section and Lymph Node Registry, University of Kiel , Germany.
b Department of Pathology , University of Tübingen , Germany.
Leuk Lymphoma. 2016;57(1):39-44. doi: 10.3109/10428194.2015.1040014.
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly occurs by definition in patients above the age of 50 years without any known underlying immunodeficiency. We investigated the incidence and clinical relevance of this subtype in Europe with special attention to the EBV-latency type. Among the 598 DLBCL, 15 EBV-positive lymphomas fulfilling the criteria of EBV-positive DLBCL of the elderly were identified (2.5%). Patients with EBV-positive DLBCL expressing EBNA2 showed a significantly poorer overall survival than patients with EBNA2-negative EBV-positive DLBCL (p = 0.0156). The incidence of EBV-positive DLBCL of the elderly in Europe is much lower than in Asian countries (2.5% of all cases of DLBCL). Interestingly, the likelihood of EBV positivity did not increase with age in patient above 50 years. Among EBV-positive DLBCL of the elderly a subgroup with EBV-latency type III expressing EBNA2 can be identified, which shows a poor outcome.
根据定义，老年型爱泼斯坦-巴尔病毒（EBV）阳性弥漫性大B细胞淋巴瘤（DLBCL）发生于年龄在50岁以上且无任何已知潜在免疫缺陷的患者中。我们调查了该亚型在欧洲的发病率及临床相关性，并特别关注EBV潜伏类型。在598例DLBCL中，确定了15例符合老年型EBV阳性DLBCL标准的EBV阳性淋巴瘤（2.5%）。表达EBNA2的EBV阳性DLBCL患者的总生存期明显低于EBNA2阴性的EBV阳性DLBCL患者（p = 0.0156）。欧洲老年型EBV阳性DLBCL的发病率远低于亚洲国家（占所有DLBCL病例的2.5%）。有趣的是，50岁以上患者中EBV阳性的可能性并未随年龄增加。在老年型EBV阳性DLBCL中，可以识别出一个表达EBNA2的EBV潜伏Ⅲ型亚组，其预后较差。
